Is Bristol-Myers Squibb (BMY) One of the Best Dividend Stocks to Invest in According to Hedge Funds?

With an annual dividend yield of 4.25%, Bristol-Myers Squibb Company (NYSE:BMY) is included among the 12 Best Dividend Stocks to Invest in According to Hedge Funds.

Is Bristol-Myers Squibb (BMY) One of the Best Dividend Stocks to Invest in According to Hedge Funds?

Bristol-Myers Squibb Company (NYSE:BMY) discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.

Bristol-Myers Squibb Company (NYSE:BMY) announced on May 20 that it was partnering with Anthropic to deploy Claude across its research, clinical development, manufacturing, commercial, and corporate functions. The agreement will provide over 30,000 BMS employees with the platform and signals a significant evolution in how the pharma company deploys AI, extending well beyond the general-purpose chat tools and toward “agentic capabilities built into the day-to-day workflows and systems that underpin its science and global operations”.

Moreover, Bristol-Myers Squibb Company (NYSE:BMY) revealed that it would also leverage Anthropic’s ​coding tool, Claude Code, and evaluate its use ⁠in research, drug development, manufacturing, and other ​commercial and medical affairs.

Greg Meyers, EVP and Chief Digital & Technology Officer at Bristol-Myers Squibb Company (NYSE:BMY), commented:

“For more than 160 years, BMS has pushed the boundaries of science to transform patients’ lives, and artificial intelligence is the single most powerful opportunity we have to accelerate that mission today. Most enterprise AI stops at the chatbot. The real prize is the untapped value still trapped behind decades of data silos, and this collaboration is how we reach it. Anthropic’s Claude gives us the agentic capabilities, pace of innovation, and security necessary to connect our systems and put that collective knowledge in the hands of every BMS employee to accelerate innovation for patients. The companies that lead the next decade of biopharma will be the ones that learn to operate fundamentally differently with AI, and BMS intends to be one of them.”

While we acknowledge the risk and potential of BMY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BMY and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: Top 12 Undervalued Dividend Stocks to Buy Now and 12 Best Blue Chip Dividend Stocks to Buy Now

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1